Aurobindo Pharma has received final USFDA approval to manufacture and market Vecuronium Bromide Injection, 10mg and 20mg for the US markets. The drug Vecuronium Bromide Injection is a generic equivalent of Organon’s Norcuron Injection. It is used as a part of general anesthesia to provide skeletal muscle relaxation during surgery or mechanical ventilation. It is also used to facilitate endotracheal intubation.
According to market estimates, the product has an estimated market size of $11 million for the twelve months ending September 2018.
Company Profile : Aurobindo Pharma Ltd
Leave a Reply